FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285019154> ?p ?o ?g. }

• W4285019154 endingPage "1755" @default.
• W4285019154 startingPage "1746" @default.
• W4285019154 abstract "Blocking immune cell gut homing via α4β7 integrin with the monoclonal antibody vedolizumab is an established therapeutic strategy in inflammatory bowel disease. However, despite promising preclinical and phase 2 clinical data, the anti-β7 antibody etrolizumab yielded disappointing results in a large phase 3 trial program in UC. Mechanistic explanations are still lacking. We have recently shown that vedolizumab is associated with residual homing of regulatory T (Treg) cells in a certain exposure range and aimed to investigate whether a similar mechanism applies for etrolizumab.We used flow cytometry, competitive dynamic adhesion, and transmigration assays to assess binding of the etrolizumab surrogate (etrolizumab-s) antibody FIB504 to Treg and effector T cells (Teff) and to explore the impact on cell trafficking.We observed only minimal differences in the binding of etrolizumab-s to Treg and Teff cells. Dynamic adhesion and transmigration of Treg and Teff cells was not substantially differentially affected at relevant concentrations. The β1+ and PI16+ Treg cells were only resistant to etrolizumab-s at low concentrations.Etrolizumab does not seem to induce notable residual trafficking of Treg cells. Thus, the Teff overweight in the inflamed gut might persist despite reduced overall T cell recruitment. This might be one piece of the puzzle to explain recent clinical results in phase 3.The efficacy of etrolizumab in phase 3 was disappointing. Our data suggest that, unlike vedolizumab, etrolizumab does not induce relevant residual trafficking of regulatory T cells. This might be one part of the explanation for recent observations in clinical trials." @default.
• W4285019154 created "2022-07-12" @default.
• W4285019154 creator A5017444688 @default.
• W4285019154 creator A5020753617 @default.
• W4285019154 creator A5027340443 @default.
• W4285019154 creator A5029918239 @default.
• W4285019154 creator A5032480207 @default.
• W4285019154 creator A5034003178 @default.
• W4285019154 creator A5044794339 @default.
• W4285019154 creator A5085014592 @default.
• W4285019154 date "2022-07-11" @default.
• W4285019154 modified "2023-10-18" @default.
• W4285019154 title "Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells" @default.
• W4285019154 cites W1506106830 @default.
• W4285019154 cites W1944355477 @default.
• W4285019154 cites W2000379621 @default.
• W4285019154 cites W2031327942 @default.
• W4285019154 cites W2031551895 @default.
• W4285019154 cites W2035809865 @default.
• W4285019154 cites W2077531651 @default.
• W4285019154 cites W2112635226 @default.
• W4285019154 cites W2116004659 @default.
• W4285019154 cites W2117258589 @default.
• W4285019154 cites W2130865756 @default.
• W4285019154 cites W2138223843 @default.
• W4285019154 cites W2144067912 @default.
• W4285019154 cites W2162766966 @default.
• W4285019154 cites W2162805528 @default.
• W4285019154 cites W2165290386 @default.
• W4285019154 cites W2325999030 @default.
• W4285019154 cites W2414026316 @default.
• W4285019154 cites W2515435336 @default.
• W4285019154 cites W2583464358 @default.
• W4285019154 cites W2586374020 @default.
• W4285019154 cites W2623221337 @default.
• W4285019154 cites W2768877681 @default.
• W4285019154 cites W2803739967 @default.
• W4285019154 cites W2809894743 @default.
• W4285019154 cites W2913992246 @default.
• W4285019154 cites W2945386610 @default.
• W4285019154 cites W2976731348 @default.
• W4285019154 cites W3028384433 @default.
• W4285019154 cites W3211709749 @default.
• W4285019154 cites W3213907938 @default.
• W4285019154 cites W3214731670 @default.
• W4285019154 cites W4211241312 @default.
• W4285019154 cites W4226191244 @default.
• W4285019154 cites W4226297186 @default.
• W4285019154 cites W4230633180 @default.
• W4285019154 doi "https://doi.org/10.1093/ibd/izac137" @default.
• W4285019154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35815779" @default.
• W4285019154 hasPublicationYear "2022" @default.
• W4285019154 type Work @default.
• W4285019154 citedByCount "4" @default.
• W4285019154 countsByYear W42850191542023 @default.
• W4285019154 crossrefType "journal-article" @default.
• W4285019154 hasAuthorship W4285019154A5017444688 @default.
• W4285019154 hasAuthorship W4285019154A5020753617 @default.
• W4285019154 hasAuthorship W4285019154A5027340443 @default.
• W4285019154 hasAuthorship W4285019154A5029918239 @default.
• W4285019154 hasAuthorship W4285019154A5032480207 @default.
• W4285019154 hasAuthorship W4285019154A5034003178 @default.
• W4285019154 hasAuthorship W4285019154A5044794339 @default.
• W4285019154 hasAuthorship W4285019154A5085014592 @default.
• W4285019154 hasConcept C126322002 @default.
• W4285019154 hasConcept C151872237 @default.
• W4285019154 hasConcept C159654299 @default.
• W4285019154 hasConcept C18903297 @default.
• W4285019154 hasConcept C203014093 @default.
• W4285019154 hasConcept C2776207728 @default.
• W4285019154 hasConcept C2778260677 @default.
• W4285019154 hasConcept C2779134260 @default.
• W4285019154 hasConcept C502942594 @default.
• W4285019154 hasConcept C51785407 @default.
• W4285019154 hasConcept C542903549 @default.
• W4285019154 hasConcept C553184892 @default.
• W4285019154 hasConcept C71924100 @default.
• W4285019154 hasConcept C86803240 @default.
• W4285019154 hasConcept C8891405 @default.
• W4285019154 hasConcept C95444343 @default.
• W4285019154 hasConceptScore W4285019154C126322002 @default.
• W4285019154 hasConceptScore W4285019154C151872237 @default.
• W4285019154 hasConceptScore W4285019154C159654299 @default.
• W4285019154 hasConceptScore W4285019154C18903297 @default.
• W4285019154 hasConceptScore W4285019154C203014093 @default.
• W4285019154 hasConceptScore W4285019154C2776207728 @default.
• W4285019154 hasConceptScore W4285019154C2778260677 @default.
• W4285019154 hasConceptScore W4285019154C2779134260 @default.
• W4285019154 hasConceptScore W4285019154C502942594 @default.
• W4285019154 hasConceptScore W4285019154C51785407 @default.
• W4285019154 hasConceptScore W4285019154C542903549 @default.
• W4285019154 hasConceptScore W4285019154C553184892 @default.
• W4285019154 hasConceptScore W4285019154C71924100 @default.
• W4285019154 hasConceptScore W4285019154C86803240 @default.
• W4285019154 hasConceptScore W4285019154C8891405 @default.
• W4285019154 hasConceptScore W4285019154C95444343 @default.
• W4285019154 hasFunder F4320306301 @default.
• W4285019154 hasFunder F4320311367 @default.

• next